RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
RenovoRx, Inc. director K. Angela Macfarlane received a grant of 55,924 stock options on October 1, 2026, bringing her reported post-transaction position to 55,924 options. The options are exercisable at $1.55 per share for RenovoRx common stock. They vest in 12 equal monthly installments beginning November 1, 2026, and expire October 1, 2036.
RenovoRx, Inc. (RNXT) granted director Robert J. Spiegel 55,924 stock options on October 1, 2026, covering 55,924 shares of common stock. The grant is reported as directly held, with 55,924 options following the transaction. The options vest in 12 equal monthly installments beginning November 1, 2026, and expire October 1, 2036.
RenovoRx, Inc. director Una S. Ryan received a grant of 55,924 stock options on October 1, 2026. The options are exercisable for Common Stock at an exercise price of $1.55 per share and expire October 1, 2036. The options are reported as held directly by Ryan.
RenovoRx, Inc. director Laurence Marton acquired 55,924 stock options on October 1, 2026, covering 55,924 shares of common stock at an exercise price of $1.55 per share. The options vest in 12 equal monthly installments beginning November 1, 2026, and expire October 1, 2036. The reported post-transaction position is 55,924 options.
RenovoRx, Inc. (symbol: RNXT) is the issuer of record for a Form 4 filing submitted to the SEC. VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. (RNXT) reported that its Chief Financial Officer, Mark Voll, received a grant of 80,000 restricted stock units (RSUs)222,380 shares of common stock directly and 97,200 shares indirectly through the Voll Family Trust. No Rule 10b5-1 trading plan is reported for this award.
RenovoRx, Inc. (RNXT) reports that its common stock has regained compliance with Nasdaq’s Minimum Bid Price Requirement under Listing Rule 5550(a)(2). The company previously received notice of non-compliance on December 31, 2025, after its closing bid price remained below $1.00 per share for 30 consecutive business days.
Nasdaq informed RenovoRx on August 20, 2026 that, for the ten consecutive business days from August 6, 2026 through August 19, 2026, the closing bid price of its common stock was $1.00 per share or greater. As a result, RenovoRx is now back in compliance with the Nasdaq minimum bid price standard and Nasdaq considers the matter closed.
RenovoRx, Inc. reported strong early commercialization momentum for its RenovoCath device while remaining deeply loss-making. Q2 2026 revenue was $909,000, up from $422,000 a year earlier, with six‑month revenue of $1.47 million versus $619,000 in 2025, reflecting broader adoption across active cancer centers.
Despite higher revenue, the company recorded a Q2 2026 net loss of $2.91 million and a six‑month net loss of $6.43 million, driven mainly by $8.06 million in operating expenses as it builds out commercial and clinical capabilities. Operating cash outflows were $6.58 million for the first half, partially offset by a March 2026 private placement that raised $10.0 million gross, leaving cash and cash equivalents of $9.48 million at June 30, 2026.
Management states current liquidity is expected to fund operations for at least 12 months from the report date, into the second half of 2027, but acknowledges that longer‑term growth, continued RenovoCath commercialization, and the Phase III TIGeR‑PaC trial for its IAG drug‑device candidate will likely require additional capital. The company also highlights multiple Orphan Drug Designations and continued progress toward completing TIGeR‑PaC, with clinical and investigator‑initiated studies intended to broaden its TAMP targeted‑delivery platform.
RenovoRx, Inc. reported record Q2 2026 revenue of $909,000, up approximately 61% from Q1 2026 and 115% from Q2 2025, driven by accelerating commercial adoption of its FDA-cleared RenovoCath device. Gross profit was $766,000, yielding an approximately 84% gross margin.
Net loss for the quarter was $2.9 million, similar to the prior year, as the company increased selling, general and administrative spending to build commercial infrastructure. Cash and cash equivalents totaled $9.5 million as of June 30, 2026, which the company believes will fund operations into the second half of 2027.
RenovoRx raised its 2026 revenue guidance to $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The company ended the quarter with 21 active commercial cancer center customers and a total commercial funnel of 63 centers. Its Phase III TIGeR-PaC trial reached full enrollment, with trial completion expected in the first half of 2027 and topline data in the second half of 2027.
RenovoRx, Inc. reported record second quarter 2026 results, with revenue of $909,000, up approximately 61% from the first quarter of 2026 and 115% from the prior-year quarter. For the first six months of 2026, revenue totaled $1.47 million, and second-quarter revenue alone represented about 83% of full-year 2025 revenue.
Gross profit was $766,000, for a gross margin of about 84%. The company recorded a net loss of $2.9 million, similar to a year earlier, and ended June 30, 2026 with $9.5 million in cash and cash equivalents, which it believes funds operations into the second half of 2027. Active commercial cancer center customers reached 21, with a total commercial funnel of 63 centers.
RenovoRx increased its 2026 revenue guidance to a range of $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The Phase III TIGeR-PaC trial of intra-arterial gemcitabine via RenovoCath has reached full enrollment, with completion expected in the first half of 2027 and topline data in the second half of 2027.